Drugs / nal-Iri
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03487016 | Feb 2019 → Jul 2022 | malignant pancreatic neoplasm | Ludwig-Maximilians - University of Munich | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nal-Iri | “the combination of liposomal irinotecan (nal-Iri) in combination with 5-FU/folinic acid (FA)” NCT03487016 ↗ |
| Known as | Irinotecan Liposomal Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03487016 ↗ |
| Route | Intravenous | “Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes” NCT03487016 ↗ |